泰林生物
(300813)
| 流通市值：15.56亿 | | | 总市值：22.16亿 |
| 流通股本：8512.61万 | | | 总股本：1.21亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 254,923,363.93 | 165,382,315.28 | 70,063,538.95 | 339,538,843.84 |
| 营业收入 | 254,923,363.93 | 165,382,315.28 | 70,063,538.95 | 339,538,843.84 |
| 二、营业总成本 | 237,825,130.92 | 148,978,158 | 66,596,113.34 | 329,644,577.8 |
| 营业成本 | 127,913,030.23 | 84,317,136.48 | 34,813,477.4 | 185,246,081.46 |
| 税金及附加 | 2,364,688.04 | 1,588,573.93 | 713,219.92 | 5,124,925.31 |
| 销售费用 | 34,801,412.29 | 19,682,491.66 | 9,044,005.62 | 46,891,489.75 |
| 管理费用 | 29,805,009.51 | 19,058,147.4 | 8,668,565.5 | 39,289,047.55 |
| 研发费用 | 44,083,917.62 | 25,664,633.42 | 14,071,990.95 | 57,209,256.09 |
| 财务费用 | -1,142,926.77 | -1,332,824.89 | -715,146.05 | -4,116,222.36 |
| 其中:利息收入 | 2,288,652.47 | 2,062,233.89 | -1,128,383.1 | 4,925,309.76 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 20,441.21 |
| 加:投资收益 | 3,351,594.95 | 1,641,315.01 | -3,198.03 | 4,356,675.93 |
| 资产处置收益 | 0 | - | - | - |
| 资产减值损失(新) | -823,906.53 | -886,249.41 | - | -3,963,381.82 |
| 信用减值损失(新) | 438,064.37 | 312,571.64 | 459,410.88 | -1,290,716.19 |
| 其他收益 | 10,796,155.77 | 4,400,416.82 | 1,451,122.45 | 7,920,808.15 |
| 四、营业利润 | 30,860,141.57 | 21,872,211.34 | 5,374,760.91 | 16,938,093.32 |
| 加:营业外收入 | 4,494.77 | 3,141.73 | 1,507.03 | 396,198.12 |
| 减:营业外支出 | 675,723.67 | 265,965.06 | 93,667.84 | 595,574.93 |
| 五、利润总额 | 30,188,912.67 | 21,609,388.01 | 5,282,600.1 | 16,738,716.51 |
| 减:所得税费用 | 2,111,661.15 | 1,236,564.32 | 442,289.27 | 452,641.81 |
| 六、净利润 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,485,445.79 |
| 少数股东损益 | - | - | - | -199,371.09 |
| 扣除非经常损益后的净利润 | 21,322,527.72 | 18,252,035.87 | 4,205,524.73 | 10,527,649.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.23 | 0.17 | 0.04 | 0.14 |
| (二)稀释每股收益 | 0.23 | 0.17 | 0.04 | 0.14 |
| 九、综合收益总额 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 |
| 归属于母公司股东的综合收益总额 | 28,077,251.52 | 20,372,823.69 | 4,840,310.83 | 16,485,445.79 |
| 归属于少数股东的综合收益总额 | - | - | - | -199,371.09 |
| 公告日期 | 2026-10-30 | 2026-08-27 | 2026-04-30 | 2026-03-27 |
| 审计意见(境内) | | | | 标准无保留意见 |